Please login to the form below

Not currently logged in
Email:
Password:

ABPI updates phase 1 clinical trial guidelines

UK pharma industry body issues first new version of guidance since 2007

Guidelines for phase 1 clinical trials (2012 edition)

The Association of the British Pharmaceutical Industry (ABPI) has updated its early-stage trial guidance for the UK pharma industry.

The new version of the Guidelines for Phase 1 Clinical Trials, the first since a major revision in 2007, was created to take account of a number of regulatory changes and ensure they remain relevant for the future.

Stephen Whitehead, chief executive of the ABPI, said: “Ten to twenty years from now there will be a whole raft of innovative new medicines saving and improving patients' lives as a result of the experimental research taking place today.

“In phase 1 research, which represents the link between scientific research and clinical medicine, the highest possible level of knowledge, standards and skills must all be brought together.

“The ABPI has produced these guidelines to help support and simplify the critical role of phase 1 research, while helping researchers ensure their work is conducted with the highest possible level of efficacy and safety.”

Most of changes to the Guidelines stem from the introduction of Good Clinical Practice (GCP), Good Manufacturing Practice (GMP) and the Clinical Trials Directive, which is based on GCP and GMP.

The Guidelines also have a section on pharmacovigilance, which has this year undergone its biggest changes in seven years as a result of new European legislation.

However, another new version of the Guidelines may soon be needed. The EMA last month published proposals for simplifying clinical trial rules and cutting down on red tape. 

• The Guidelines for Phase 1 Clinical Trials can be downloaded from the ABPI website

15th August 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

Precision medicine and the changing role of the healthcare professional
The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of...
How will Sustainability and Transformation Plans (STPs) change the NHS commissioning landscape?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, take a look at new commissioning structures and what they mean for pharma...
eyeforpharma Barcelona 2017 highlights: Industry at the brink of transformation
Hear what Anthill's delegates reported back from the biggest eyeforpharma Barcelona yet....

Infographics